Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Holdings

4,878.88
+67.471.40%
Number of Gainers:33
Number of Losers:30
Number of Flat:2
PE:- -
High:4,911.82
Open:4,823.92
Low:4,820.11
Close:4,811.41
Volume:301.58M
Turnover:33.33B
Market Cap:8.72T
Float Cap:8.26T

Loading ...

Dyne Therapeutics to Present One-Year Phase 1/2 Achieve Data for DM1 Drug DYNE-101 at Upcoming Meetings

Reuters
·
Sep 08

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 Achieve Trial of Z-Basivarsen (Dyne-101) for Myotonic Dystrophy Type 1 (Dm1) at Upcoming Medical Meetings

THOMSON REUTERS
·
Sep 08

Alibaba Reportedly Merges B2B Units Under New Leadership, No Official Comment Yet

Deep News
·
Sep 08

Kura Oncology Appoints Jennifer Fulk as New CFO

TIPRANKS
·
Sep 08

Analysts Offer Insights on Technology Companies: Shopify (SHOP) and UiPath (PATH)

TIPRANKS
·
Sep 08

Kura Oncology Names Jennifer Fulk Chief Financial Officer

Dow Jones
·
Sep 08

HSBC keeps Buy on Apple into tomorrow’s iPhone launch event

TIPRANKS
·
Sep 08

Arete Downgrades JD.com to Neutral From Buy, Adjusts PT to $30 From $36

MT Newswires Live
·
Sep 08

Regenxbio to Join Baird, Morgan Stanley Healthcare Investor Conferences

Reuters
·
Sep 08

Nkarta to Present Initial Phase 1/2 Autoimmune Data for CAR-NK Therapy Nkx019 at ACR Convergence 2026

Reuters
·
Sep 08

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

THOMSON REUTERS
·
Sep 08

Odds ‘4 to 1’ against Apple as Ternus takes helm, says Needham

TIPRANKS
·
Sep 08

UiPath initiated with a Buy at Citi

TIPRANKS
·
Sep 08

MoffettNathanson Adjusts Price Target on Apple to $304 From $270, Keeps Neutral Rating

MT Newswires Live
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Sep 08

Sarepta, Dyne Sink After Novartis Muscle Disorder Trial Failure

Reuters
·
Sep 08

Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Tuesday; Bloom Energy, Oracle to Open Higher

MT Newswires Live
·
Sep 08

Beam Therapeutics’ BEAM-302 shows efficacy in Phase 1/2 AATD trial

TIPRANKS
·
Sep 08

Sarepta Therapeutics Down 15.6%, Dyne Therapeutics Down 29%

THOMSON REUTERS
·
Sep 08

Shares of Some Drug Developers Fall Premarket After Novartis Late-Stage Muscle Disorder Trial Fails

THOMSON REUTERS
·
Sep 08